{
    "id": 16856,
    "fullName": "MAP2K1 C121S",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 C121S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). C121S confers a gain of function on the Map2k1 protein as demonstrated by increased Erk1/2 (PMID: 25899310) and Mek phosphorylation in culture and has been demonstrated to confer acquired resistance to Raf and Mek inhibitors (PMID: 21383288, PMID: 24448821, PMID: 29483135, PMID: 29753091).",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                },
                {
                    "id": 12176,
                    "pubMedId": 25899310,
                    "title": "MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25899310"
                },
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                },
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11332,
                    "pubMedId": 29483135,
                    "title": "Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29483135"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "C121S",
    "createDate": "01/19/2016",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 173331,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66436815T>A",
        "cDna": "c.361T>A",
        "protein": "p.C121S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14255,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 C121S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14263,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 C121S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14277,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 C121S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14284,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 C121S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 2617,
                "therapyName": "PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14291,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 17134,
                "profileName": "MAP2K1 C121S"
            },
            "therapy": {
                "id": 658,
                "therapyName": "AZD8330",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7037,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4030,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12159,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17134,
            "profileName": "MAP2K1 C121S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17135,
            "profileName": "BRAF V600E MAP2K1 C121S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173331,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66436815T>A",
            "cDna": "c.361T>A",
            "protein": "p.C121S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173332,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66436815T>A",
            "cDna": "c.361T>A",
            "protein": "p.C121S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}